The United States represents the largest share of the recombinant albumin market in North America, driven by its well-established biopharmaceutical industry, extensive research infrastructure, and growing investments in advanced therapeutic development. The increasing adoption of recombinant albumin in vaccine production, monoclonal antibody manufacturing, stem cell research, and regenerative...